Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)

Tariq Kewan(Yale University), Amer M. Zeidan(Yale Cancer Center), Gail J. Roboz(Cornell University), Maximilian Stahl(Harvard University), Hetty E. Carraway(Cleveland Clinic), David A. Sallman(Moffitt Cancer Center), Constantine Logothetis(Saint Louis University), Amy E. DeZern(Johns Hopkins University), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Eric Padron(Moffitt Cancer Center), Maria L. Amaya(University of Colorado Denver), Jessica M. Stempel(University of New Haven), Zhuoer Xie(Mayo Clinic), Ondřej Bláha(Yale University), Michael R. Savona(Vanderbilt University), Mikkael A. Sekeres(University of Miami), Namrata S. Chandhok(Sylvester Comprehensive Cancer Center), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Benjamin Rolles(Brigham and Women's Hospital), Rahul Ramaswamy(Vanderbilt University Medical Center), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Jaroslaw P. Maciejewski(Cleveland Clinic), Matteo Giovanni Della Porta(Humanitas University), Rory M. Shallis(Smilow Cancer Hospital), Amyah C. Harris(Dana-Farber Cancer Institute), Najla H. Al Ali(Moffitt Cancer Center), Andrew M. Brunner(Harvard University), Ameera Rose(Cleveland Clinic), Rami S. Komrokji(Moffitt Cancer Center)
Blood
November 2, 2023
Cited by 0


Related Papers